Program areas at Subcutaneous Drug Development and Delivery Consortium
Bioavailability collaborative research project: "bioavailability prediction based on pbpk modeling leveraging data obtained via open flow microperfusion (ofm) technology" first rfp for sc Consortium translated to collaboration with joanneum/ bionotus - in-vivo studies completed and preliminary model has been developed; shared key learnings including legal framework for future rfps; technology areas scouted to focus scope of future rfps.
Patient preference and experience: completed comprehensive draft of manuscript, summarizing the patient treatment journey starting at diagnosis, including consideration of patient characteristics and sc product design attributes to inform sc Drug Delivery design and Development. The manuscript also offers future perspectives to fill data gaps to advance patient-centric sc Drug Delivery. Initiated conversations around the next priorities, gaining agreement to prioritize additional patient research.
High dose high volume: "towards more tolerable Subcutaneous administration: review of contributing factors for improving combination product design" completion of literature search and landscape of hdhv pain knowledge; drafted a manuscript reviewing sc pain on injection for high dose and high volume drugs; identified gaps and made recommendations for future sc product design.
Personnel at Subcutaneous Drug Development and Delivery Consortium
| Name | Title | Compensation | Date of data |
|---|
| Donna French | President | $0 | 2023-10-24 |
| Sachin Mittal | Vice President | $0 | 2022-12-31 |
| David Kang | Treasurer | $0 | 2022-09-01 |
| David Collins | President | $0 | 2022-08-10 |
Financials for Subcutaneous Drug Development and Delivery Consortium
| Revenues | FYE 12/2023 | FYE 12/2022 | % Change |
|---|
| Total grants, contributions, etc. | $0 | $0 | - |
| Program services | $760,000 | $406,250 | 87.1% |
| Investment income and dividends | $0 | $0 | - |
| Tax-exempt bond proceeds | $0 | $0 | - |
| Royalty revenue | $0 | $0 | - |
| Net rental income | $0 | $0 | - |
| Net gain from sale of non-inventory assets | $0 | $0 | - |
| Net income from fundraising events | $0 | $0 | - |
| Net income from gaming activities | $0 | $0 | - |
| Net income from sales of inventory | $0 | $0 | - |
| Miscellaneous revenues | $0 | $0 | - |
| Total revenues | $760,000 | $406,250 | 87.1% |
Organizations like Subcutaneous Drug Development and Delivery Consortium
| Organization | Type | Location | Revenue |
|---|
| Fats and Proteins Research Foundation | 501(c)(6) | Alexandria, VA | $805,805 |
| Research and Development Associates for Military Food and Packaging Systems | 501(c)(6) | San Antonio, TX | $628,865 |
| Intrepid Alliance | 501(c)(6) | Cambridge, MA | $1,500,000 |
| Fractionation Research Incorporated (FRI) | 501(c)(6) | Stillwater, OK | $3,795,339 |
| International Fine Particle Research Ins | 501(c)(6) | Wilmington, DE | $902,500 |
| WaterStart | 501(c)(6) | Las Vegas, NV | $508,109 |
| Materials Technology Institute (MTI) | 501(c)(6) | Saint Louis, MO | $2,556,624 |
| Engineered Wood Research Foundation | 501(c)(6) | Tacoma, WA | $338,895 |
| IBEW Local 364-neca Elec Ind Labor Management Cooperation Committee | 501(c)(6) | Rockford, IL | $905,548 |
| Washington 811 | 501(c)(6) | South Colby, WA | $3,750,856 |
Data update history
October 23, 2024
Used new vendors
Identified 1 new vendor, including
November 27, 2023
Posted financials
Added Form 990 for fiscal year 2022
November 27, 2023
Updated personnel
Identified 1 new personnel
August 14, 2023
Posted financials
Added Form 990 for fiscal year 2021
May 14, 2023
Updated personnel
Identified 15 new personnel
Nonprofit Types
Business and community development organizationsResearch centers
Issues
Science and technologyPublic policyBusiness and industry
Characteristics
MembershipsConducts researchState / local levelNo full-time employees
General information
- Address
- 3855 SW 153rd Dr
- Beaverton, OR 97003
- Metro area
- Portland-Vancouver-Hillsboro, OR-WA
- County
- Washington County, OR
- Website URL
- subcutaneousconsortium.org/Â
- Phone
- (503) 619-0505
IRS details
- EIN
- 85-0837695
- Fiscal year end
- December
- Taxreturn type
- Form 990
- Year formed
- 2020
- Eligible to receive tax-deductible contributions (Pub 78)
- No
Categorization
- NTEE code, primary
- S40: Business and Industry
- NAICS code, primary
- 5417: Scientific Research and Development Services
- Parent/child status
- Independent
Free account sign-up
Want updates when Subcutaneous Drug Development and Delivery Consortium has new information, or want to find more organizations like Subcutaneous Drug Development and Delivery Consortium?
Create free Cause IQ account